Summary

The global Multiplex Assays Market is projected to reach USD 4.3 billion by 2026 from USD 3.0 billion in 2021, at a CAGR of 7.6% during the forecast period. Market growth is mainly driven by factors such as the increasing adoption of companion diagnostics, the increasing incidence of chronic and infectious diseases, the growing awareness of the disease diagnosis, and the need for effective analytical platforms in research and clinical diagnostics to reduce the operational costs and the time taken for diagnosis. However, the high cost of multiplex assay equipment, stringent regulations and standards, and issues in the standardization of multiplex assays design are the major factors restraining the growth of this market.

“Product and Service accounted for the largest share of the Multiplex Assays Market and is expected to grow at the highest CAGR in the forecast period.”

Based on product & service, the multiplex assays market is segmented into instruments, consumables, and software & services. In 2020, the consumables segment is expected to account for the largest share of the market; it is also the fastest-growing segment of the multiplex assays market. This can be attributed to the recurring purchase of assays and reagents for increasing research applications.

“Protein-based multiplex assays segment is expected to account for the largest share of the global multiplex assays market and is expected to grow at the highest CAGR in the forecast period.”
Based on type, the global multiplex assays market is divided into protein-based multiplex assays, nucleic acid-based multiplex assays, and cell-based multiplex assays. In 2020, the protein-based multiplex assays segment is expected to account for the largest share of the global multiplex assays market. This large share can be attributed to the increasing focus on proteomics studies for biomarker research and clinical diagnostics.

“Flow cytometry segment is expected to account for the largest share of the global multiplex assays market and is expected to grow at the highest CAGR in the forecast period.”
On the basis of technology, the global multiplex assays market is divided into flow cytometry, multiplex RT PCR, luminescence, fluorescence detection, and other technologies. In 2020, the flow cytometry segment is expected to account for the largest share of the global multiplex assays market. The large share can be attributed to the wide applications of flow cytometry in the detection and measurement of protein expression, RNA, and cell health status (cell viability & toxicity) alongside the characterization and identification of various cell types.

“Research & development companies account for the largest share of the Multiplex Assays Market in 2020 and is expected to grow at the fastest CAGR in the forecast period.”
On the basis of application, the global multiplex assays market is divided into research & development and clinical diagnostics. In 2020, the research & development segment is expected to account for the largest share of the global multiplex assays market. This large share can be attributed to the wide applications of multiplex assay technologies in research & development functions.

“Pharmaceutical & biotechnology companies account for the largest share of the Multiplex Assays Market in 2020 and is expected to grow at the fastest CAGR in the forecast period.”
Based on end user, the multiplex assays market is segmented into pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories and other end users. In 2020, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global multiplex assays market. This large share can be attributed to the increasing adoption of multiplex assays in drug discovery and development by pharmaceuticals and the growing focus of biotechnology companies on developing biosimilars and monoclonal antibodies.
“North America will dominate the market during the forecast period.”
Geographically, the Multiplex Assays Market is segmented into four major regions, namely, North America (US and Canada), Europe, Asia Pacific, and Rest of the world. North America was the largest regional market for Multiplex Assays Market in 2020. North America is expected to account for the largest share of the multiplex assays market in 2020, followed by Europe. The dominant share of the North American market is primarily attributed to its established pharmaceutical industry, presence of leading pharmaceutical and biotechnology companies, and high R&D investment.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type - Tier 1: 42%, Tier 2: 37%, and Tier 3: 21%
• By Designation - C-level: 34%, D-level: 42%, and Others: 23%
• By Region - North America: 32%, Europe: 30%, Asia Pacific: 24%, and Rest of the World: 14%
List of Companies Profiled in the Report
• Luminex Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• Illumina, Inc (US)
• Bio-Rad Laboratories, Inc. (US)
• Qiagen N.V. (Netherlands)
• Abcam plc (UK)
• Becton, Dickinson and Company (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Meso Scale Diagnostics (US)
• Randox Laboratories (UK)
• Quanterix (US)
• Bio-Techne Corporation (US)
• Olink (Sweden)
• DiaSorin S.p.A. (Italy)
• Seegene (South Korea)
• Promega Corporation (US)
• Siemens Healthineers (Germany)
• PerkinElmer, Inc. (US)
• Shimadzu Biotech (Japan)
• Antigenix America, Inc. (US)
• Enzo Life Sciences, Inc. (US)
• Boster Biological Technology (US)
• AYOXXA Biosystems GmbH (Germany)
• Cayman Chemical Company (US).

Research Coverage:
This report provides a detailed picture of the global multiplex assays market. It aims at estimating the size and future growth potential of the market across different segments, such as type, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total multiplex assays market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on multiplex assays offered by the top 15 players in the multiplex assays market. The report analyses the multiplex assays market by product & service, type, technology, application, end user, and region

• Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various multiplex assays across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assays market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the multiplex assays market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 YEARS CONSIDERED FOR THE STUDY 34
1.4 CURRENCY 34
TABLE 2 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 34
1.5 STAKEHOLDERS 35
1.6 LIMITATIONS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.2 PRIMARY DATA 38
2.2.1 KEY DATA FROM PRIMARY SOURCES 39
2.2.1.1 Key data from primary sources 40
2.2.1.2 Key industry insights 41
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 42
2.3 MARKET SIZE ESTIMATION 42
FIGURE 3 MULTIPLEX ASSAYS MARKET – REVENUE SHARE ANALYSIS
ILLUSTRATION: ILLUMINA, INC. 43
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF MULTIPLEX ASSAY PRODUCTS 44
FIGURE 5 CAGR PROJECTIONS 45
FIGURE 6 TOP-DOWN APPROACH 46
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.4.1 SECONDARY DATA 47
2.4.2 PRIMARY DATA 47
2.5 DATA TRIANGULATION METHODOLOGY 48
FIGURE 7 DATA TRIANGULATION 48
2.6 MARKET SHARE ANALYSIS 49
2.7 ASSUMPTIONS FOR THE STUDY 49
2.8 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 50
2.8.1 COVID-19-SPECIFIC ASSUMPTIONS 51
2.9 LIMITATIONS 51
2.10 RISK ASSESSMENT 52
TABLE 3 RISK ASSESSMENT 52
2.11 COVID-19 HEALTH ASSESSMENT 52
2.12 COVID-19 ECONOMIC ASSESSMENT 52
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 52
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 53
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 54
2.14 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE MULTIPLEX ASSAYS MARKET 55
3 EXECUTIVE SUMMARY 56
FIGURE 10 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD BILLION) 56
FIGURE 11 MULTIPLEX ASSAYS MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION ) 57
FIGURE 12 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD BILLION) 57
FIGURE 13 MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021 VS. 2026 (USD BILLION ) 58
FIGURE 14 MULTIPLEX ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD BILLION) 58
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE MULTIPLEX ASSAYS MARKET
(2021–2026) 59
4 PREMIUM INSIGHTS 60
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW 60
FIGURE 16 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE THE MARKET GROWTH 60
4.2 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION AND COUNTRY (2020) 61
FIGURE 17 R&D TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN MULTIPLEX ASSAYS MARKET IN 2020 61
4.3 MULTIPLEX ASSAYS MARKET, BY REGION (2021 VS. 2026) 61
FIGURE 18 NORTH AMERICA TO DOMINATE THE MULTIPLEX ASSAYS MARKET IN 2026 61
4.4 GEOGRAPHICAL SNAPSHOT OF THE MULTIPLEX ASSAYS MARKET 62
FIGURE 19 APAC TO BE THE FASTEST-GROWING MARKET FROM 2021 TO 2026 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 20 GLOBAL MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Increasing use of multiplex assays in companion diagnostics 64
5.2.1.2 Increasing advantages over singleplex and traditional assays 64
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 65
 
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019, 2030, AND 2045 65
TABLE 4 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 66
TABLE 5 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR THE DIAGNOSIS OF SARS-COV-2 66
5.2.2 RESTRAINTS 68
5.2.2.1 Increasing costs of equipment 68
5.2.2.2 Growing number of stringent regulations and standards 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics 68
5.2.3.2 Rising need for high-throughput and automated systems 68
5.2.4 CHALLENGES 69
5.2.4.1 Increasing dearth of skilled professionals 69
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT AND SERVICE 70
6.1 INTRODUCTION 71
TABLE 6 MULTIPLEX ASSAYS MARKET, BY PRODUCT AND SERVICE,
2016–2020 (USD MILLION) 71
TABLE 7 MULTIPLEX ASSAYS MARKET, BY PRODUCT AND SERVICE,
2021–2026 (USD MILLION) 71
6.2 CONSUMABLES 71
TABLE 8 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION,
2016–2020 (USD MILLION) 72
TABLE 9 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION,
2021–2026 (USD MILLION) 72
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 73
TABLE 11 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 73
6.3 INSTRUMENTS 73
TABLE 12 MULTIPLEX ASSAY INSTRUMENTS MARKET, BY REGION,
2016–2020 (USD MILLION) 74
TABLE 13 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION,
2021–2026 (USD MILLION) 74
TABLE 14 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 74
TABLE 15 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 75
6.4 SOFTWARE & SERVICES 75
TABLE 16 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION,
2016–2020 (USD MILLION) 75
TABLE 17 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 76
TABLE 18 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET,
BY COUNTRY, 2016–2020 (USD MILLION) 76
TABLE 19 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET,
BY COUNTRY, 2021–2026 (USD MILLION) 76
7 MULTIPLEX ASSAYS MARKET, BY TYPE 77
7.1 INTRODUCTION 78
TABLE 20 MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 78
TABLE 21 MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 78
7.2 PROTEIN MULTIPLEX ASSAYS 78
TABLE 22 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 79
TABLE 23 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 79
TABLE 24 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 79
TABLE 25 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION,
2021–2026(USD MILLION) 80
TABLE 26 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 80
TABLE 27 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 80
7.2.1 PLANAR PROTEIN ASSAYS 81
TABLE 28 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 81
TABLE 29 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2021–2026(USD MILLION) 81
TABLE 30 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY,
2016–2020 (USD MILLION) 82
TABLE 31 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 82
7.2.2 BEAD-BASED PROTEIN ASSAYS 82
TABLE 32 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 83
TABLE 33 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 83
TABLE 34 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 83
TABLE 35 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 84
7.2.3 OTHER PROTEIN ASSAYS 84
TABLE 36 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 84
TABLE 37 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2021–2026(USD MILLION) 85
TABLE 38 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY,
2016–2020 (USD MILLION) 85
TABLE 39 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 85
7.3 NUCLEIC ACID MULTIPLEX ASSAYS 86
TABLE 40 SOME OF THE FDA AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS AUTHORIZED FOR THE SIMULTANEOUS DETECTION OF INFLUENZA VIRUSES AND SARS-COV-2 86
TABLE 41 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE,
2016–2020 (USD MILLION) 88
TABLE 42 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE,
2021–2026 (USD MILLION) 89
TABLE 43 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 89
TABLE 44 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 89
TABLE 45 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 90
TABLE 46 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 90
7.3.1 PLANAR NUCLEIC ACID ASSAYS 90
TABLE 47 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 91
TABLE 48 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 91
TABLE 49 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 91
TABLE 50 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 92
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS 92
TABLE 51 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 92
TABLE 52 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 93
TABLE 53 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET,
BY COUNTRY, 2016–2020 (USD MILLION) 93
TABLE 54 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET,
BY COUNTRY, 2021–2026 (USD MILLION) 93
7.3.3 OTHER NUCLEIC ACID ASSAYS 94
TABLE 55 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 94
TABLE 56 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 94
TABLE 57 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET,
BY COUNTRY, 2016–2020 (USD MILLION) 94
TABLE 58 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 95
7.4 CELL-BASED MULTIPLEX ASSAYS 95
TABLE 59 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 95
TABLE 60 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 96
TABLE 61 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 96
TABLE 62 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 96
 
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY 97
8.1 INTRODUCTION 98
TABLE 63 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 98
TABLE 64 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 98
8.2 FLOW CYTOMETRY 99
TABLE 65 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION,
2016–2020 (USD MILLION) 99
TABLE 66 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION,
2021–2026 (USD MILLION) 100
TABLE 67 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2016–2020 (USD MILLION) 100
TABLE 68 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2021–2026 (USD MILLION) 100
8.3 FLUORESCENCE DETECTION 101
TABLE 69 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2016–2020 (USD MILLION) 101
TABLE 70 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2021–2026 (USD MILLION) 101
TABLE 71 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2016–2020 (USD MILLION) 102
TABLE 72 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2021–2026 (USD MILLION) 102
8.4 LUMINESCENCE 102
TABLE 73 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION,
2016–2020 (USD MILLION) 103
TABLE 74 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION,
2021–2026 (USD MILLION) 103
TABLE 75 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE,
BY COUNTRY, 2016–2020 (USD MILLION) 103
TABLE 76 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE,
BY COUNTRY, 2021–2026 (USD MILLION) 104
8.5 MULTIPLEX REAL-TIME PCR 104
TABLE 77 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX RT PCR, BY REGION,
2016–2020 (USD MILLION) 105
TABLE 78 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX RT PCR, BY REGION,
2021–2026 (USD MILLION) 105
TABLE 79 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX RT PCR,
BY COUNTRY, 2016–2020 (USD MILLION) 105
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX RT PCR,
BY COUNTRY, 2021–2026 (USD MILLION) 106
8.6 OTHER TECHNOLOGIES 106
TABLE 81 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2020 (USD MILLION) 107
TABLE 82 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION) 107
TABLE 83 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2020 (USD MILLION) 107
TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION) 108
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION 109
9.1 INTRODUCTION 110
TABLE 85 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2016–2020 (USD MILLION) 110
TABLE 86 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 110
9.2 RESEARCH & DEVELOPMENT 111
TABLE 87 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2016–2020 (USD MILLION) 111
TABLE 88 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2021–2026 (USD MILLION) 111
TABLE 89 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2016–2020 (USD MILLION) 111
TABLE 90 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2021–2026 (USD MILLION) 112
TABLE 91 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2016–2020 (USD MILLION) 112
TABLE 92 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2021–2026 (USD MILLION) 112
9.2.1 DRUG DISCOVERY & DEVELOPMENT 113
TABLE 93 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY REGION, 2016–2020 (USD MILLION) 113
TABLE 94 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY REGION, 2021–2026 (USD MILLION) 113
TABLE 95 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2016–2020 (USD MILLION) 114
TABLE 96 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2026 (USD MILLION) 114
9.2.2 BIOMARKER DISCOVERY & VALIDATION 114
TABLE 97 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION,
BY REGION, 2016–2020 (USD MILLION) 115
TABLE 98 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION,
BY REGION, 2021–2026 (USD MILLION) 115
TABLE 99 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2016–2020 (USD MILLION) 115
TABLE 100 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2021–2026 (USD MILLION) 116
9.3 CLINICAL DIAGNOSTICS 116
TABLE 101 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2016–2020 (USD MILLION) 116
TABLE 102 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2021–2026 (USD MILLION) 117
TABLE 103 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION) 117
TABLE 104 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION) 118
TABLE 105 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 118
TABLE 106 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 118
9.3.1 INFECTIOUS DISEASES 119
TABLE 107 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,
BY REGION, 2016–2020 (USD MILLION) 120
TABLE 108 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,
BY REGION, 2021–2026 (USD MILLION) 120
TABLE 109 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 120
TABLE 110 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 121
9.3.2 CANCER 121
TABLE 111 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 122
TABLE 112 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION) 122
TABLE 113 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION) 122
TABLE 114 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 123
TABLE 115 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 123
9.3.3 CARDIOVASCULAR DISEASES 123
TABLE 116 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION) 124
TABLE 117 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION) 124
TABLE 118 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 124
TABLE 119 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 125
9.3.4 AUTOIMMUNE DISEASES 125
TABLE 120 PREVALENCE OF SOME AUTOIMMUNE DISEASES 125
TABLE 121 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS,
BY REGION, 2016–2020 (USD MILLION) 126
TABLE 122 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS,
BY REGION, 2021–2026 (USD MILLION) 126
TABLE 123 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 127
TABLE 124 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 127
9.3.5 NERVOUS SYSTEM DISORDERS 127
TABLE 125 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION) 128
TABLE 126 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION) 128
TABLE 127 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION) 128
TABLE 128 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION) 129
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS 129
TABLE 129 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION) 129
TABLE 130 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION) 130
TABLE 131 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY COUNTRY,
2016–2020 (USD MILLION) 130
TABLE 132 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY COUNTRY,
2021–2026 (USD MILLION) 130
9.3.7 OTHER DISEASES 131
TABLE 133 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION,
2016–2020 (USD MILLION) 131
TABLE 134 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION,
2021–2026 (USD MILLION) 131
TABLE 135 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2016–2020 (USD MILLION) 132
TABLE 136 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2021–2026 (USD MILLION) 132
10 MULTIPLEX ASSAYS MARKET, BY END USER 133
10.1 INTRODUCTION 134
TABLE 137 MULTIPLEX ASSAYS MARKET, BY END USER, 2016–2020 (USD MILLION) 134
TABLE 138 MULTIPLEX ASSAYS MARKET, BY END USER, 2021–2026(USD MILLION) 134
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 135
TABLE 139 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2020 (USD MILLION) 135
TABLE 140 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2026 (USD MILLION) 135
TABLE 141 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2020 (USD MILLION) 136
TABLE 142 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION) 136
10.3 HOSPITALS & RESEARCH INSTITUTES 136
TABLE 143 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES,
BY REGION, 2016–2020 (USD MILLION) 137
TABLE 144 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES,
BY REGION, 2021–2026 (USD MILLION) 137
TABLE 145 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITAL & RESEARCH INSTITUTES, BY COUNTRY, 2016–2020 (USD MILLION) 138
TABLE 146 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITAL & RESEARCH INSTITUTES, BY COUNTRY, 2021–2026 (USD MILLION) 138
 
10.4 REFERENCE LABORATORIES 138
TABLE 147 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2016–2020 (USD MILLION) 139
TABLE 148 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 139
TABLE 149 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2016–2020 (USD MILLION) 139
TABLE 150 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION) 140
10.5 OTHER END USERS 140
TABLE 151 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION,
2016–2020 (USD MILLION) 141
TABLE 152 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION,
2021–2026 (USD MILLION) 141
TABLE 153 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS,
BY COUNTRY, 2016–2020 (USD MILLION) 141
TABLE 154 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS,
BY COUNTRY, 2021–2026 (USD MILLION) 142
11 MULTIPLEX ASSAYS MARKET, BY REGION 143
11.1 INTRODUCTION 144
TABLE 155 MULTIPLEX ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 144
TABLE 156 MULTIPLEX ASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 144
11.2 NORTH AMERICA 145
FIGURE 22 NORTH AMERICA: MULTIPLEX ASSAYS MARKET SNAPSHOT 146
TABLE 157 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY,
2016–2020 (USD MILLION) 147
TABLE 158 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 147
TABLE 159 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION) 147
TABLE 160 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 148
TABLE 161 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE,
2016–2020 (USD MILLION) 148
TABLE 162 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE,
2021–2026 (USD MILLION) 148
TABLE 163 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 149
TABLE 164 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 149
TABLE 165 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 149
TABLE 166 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 150
TABLE 167 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER,
2016–2020 (USD MILLION) 150
TABLE 168 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER,
2021–2026 (USD MILLION) 150
11.2.1 US 151
TABLE 169 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2016–2020 (USD MILLION) 151
TABLE 170 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 152
TABLE 171 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 152
TABLE 172 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 152
TABLE 173 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 153
TABLE 174 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 153
TABLE 175 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 153
TABLE 176 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 154
TABLE 177 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2016–2020 (USD MILLION) 154
TABLE 178 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2021–2026 (USD MILLION) 154
11.2.2 CANADA 155
TABLE 179 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2016–2020 (USD MILLION) 155
TABLE 180 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 155
TABLE 181 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 156
TABLE 182 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 156
TABLE 183 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 156
TABLE 184 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 157
TABLE 185 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 157
TABLE 186 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 157
TABLE 187 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER,
2016–2020 (USD MILLION) 158
TABLE 188 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER,
2021–2026 (USD MILLION) 158
11.3 EUROPE 158
TABLE 189 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2016–2020 (USD MILLION) 160
TABLE 190 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 160
TABLE 191 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 160
TABLE 192 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 161
TABLE 193 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 161
TABLE 194 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 161
TABLE 195 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 162
TABLE 196 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 162
TABLE 197 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER,
2016–2020 (USD MILLION) 162
TABLE 198 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER,
2021–2026 (USD MILLION) 163
11.4 ASIA PACIFIC 163
FIGURE 23 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT 164
TABLE 199 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2016–2020 (USD MILLION) 165
TABLE 200 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 165
TABLE 201 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE,
2016–2020 (USD MILLION) 165
TABLE 202 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE,
2021–2026 (USD MILLION) 166
TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 166
TABLE 204 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 166
TABLE 205 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 167
TABLE 206 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 167
TABLE 207 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER,
2016–2020 (USD MILLION) 167
TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER,
2021–2026 (USD MILLION) 168
11.5 REST OF THE WORLD 168
TABLE 209 ROW: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2016–2020 (USD MILLION) 169
TABLE 210 ROW: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 169
TABLE 211 ROW: MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 170
TABLE 212 ROW: MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 170
TABLE 213 ROW: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 170
TABLE 214 ROW: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 171
TABLE 215 ROW: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2016–2020 (USD MILLION) 171
TABLE 216 ROW: MULTIPLEX ASSAYS MARKET, BY APPLICATION,
2021–2026 (USD MILLION) 171
TABLE 217 ROW: MULTIPLEX ASSAYS MARKET, BY END USER,
2016–2020 (USD MILLION) 172
TABLE 218 ROW: MULTIPLEX ASSAYS MARKET, BY END USER,
2021–2026 (USD MILLION) 172
12 COMPETITIVE LANDSCAPE 173
12.1 OVERVIEW 173
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 173
12.2.1 OVERVIEW OF THE STRATEGIES ADOPTED BY KEY PLAYERS IN THE MULTIPLEX ASSAYS MARKET, 2018 TO 2021 173
12.3 MARKET RANKING ANALYSIS, 2020 176
FIGURE 24 MULTIPLEX MARKET SHARE ANALYSIS, 2020 176
TABLE 219 MULTIPLEX ASSAYS MARKET: DEGREE OF COMPETITION 177
12.4 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS) 178
12.4.1 STARS 178
12.4.2 PERVASIVE PLAYERS 178
12.4.3 EMERGING LEADERS 179
12.4.4 PARTICIPANTS 179
FIGURE 25 MULTIPLEX ASSAYS MARKET (GLOBAL):
COMPANY EVALUATION QUADRANT, 2020 179
12.5 COMPANY EVALUATION QUADRANT (SMES/STARTUPS) 180
12.5.1 PROGRESSIVE COMPANIES 180
12.5.2 STARTING BLOCKS 180
12.5.3 RESPONSIVE COMPANIES 180
12.5.4 DYNAMIC COMPANIES 180
FIGURE 26 MULTIPLEX ASSAYS MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS/SMES, 2020 181
12.6 COMPETITIVE SITUATION AND TRENDS 182
12.6.1 PRODUCT LAUNCHES AND APPROVALS 182
TABLE 220 PRODUCT LAUNCHES AND APPROVALS, 2018–2021 182
12.6.2 DEALS 183
TABLE 221 DEALS, 2018–2021 183
12.6.3 OTHER DEVELOPMENTS 184
TABLE 222 OTHER DEVELOPMENTS, 2018–2021 184
13 COMPANY PROFILES 186
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 ILLUMINA, INC. 186
TABLE 223 ILLUMINA, INC.: BUSINESS OVERVIEW 186
FIGURE 27 COMPANY SNAPSHOT: ILLUMINA, INC. (2020) 187
13.2 LUMINEX CORPORATION 193
TABLE 224 LUMINEX CORPORATION: BUSINESS OVERVIEW 193
FIGURE 28 LUMINEX CORPORATION: COMPANY SNAPSHOT (2020) 193
 
13.3 THERMO FISHER SCIENTIFIC INC. 197
TABLE 225 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 197
FIGURE 29 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC INC. (2020) 198
13.4 BIO-RAD LABORATORIES, INC. 203
TABLE 226 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 203
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2020) 204
13.5 BECTON DICKINSON AND COMPANY 209
TABLE 227 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW 209
FIGURE 31 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2020) 210
13.6 QIAGEN N.V. 214
TABLE 228 QIAGEN N.V.: BUSINESS OVERVIEW 214
FIGURE 32 COMPANY SNAPSHOT: QIAGEN N.V. (2020) 215
13.7 ABCAM PLC 218
TABLE 229 ABCAM PLC.: BUSINESS OVERVIEW 218
FIGURE 33 COMPANY SNAPSHOT: ABCAM PLC (2020) 219
13.8 MERCK KGAA 223
TABLE 230 MERCK KGAA.: BUSINESS OVERVIEW 223
FIGURE 34 COMPANY SNAPSHOT: MERCK KGAA (2020) 224
13.9 AGILENT TECHNOLOGIES INC. 227
TABLE 231 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 227
FIGURE 35 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2020) 228
13.10 QUANTERIX 231
TABLE 232 QUANTERIX.: BUSINESS OVERVIEW 231
FIGURE 36 COMPANY SNAPSHOT: QUANTERIX (2020) 232
13.11 DIASORIN S.P.A. 234
TABLE 233 DIASORIN S.P.A.: BUSINESS OVERVIEW 234
FIGURE 37 COMPANY SNAPSHOT: DIASORIN S.P.A. (2020) 235
13.12 BIO-TECHNE CORPORATION 237
TABLE 234 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 237
FIGURE 38 COMPANY SNAPSHOT: BIO-TECHNE CORPORATION (2020) 238
13.13 MESO SCALE DIAGNOSTICS, LLC 241
TABLE 235 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 241
13.14 RANDOX LABORATORIES LTD. 243
TABLE 236 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 243
13.15 OLINK 245
TABLE 237 OLINK: BUSINESS OVERVIEW 245
13.16 OTHER PLAYERS 247
13.16.1 SEEGENE INC. 247
TABLE 238 SEEGENE INC.: COMPANY OVERVIEW 247
13.16.2 PROMEGA CORPORATION 248
TABLE 239 PROMEGA CORPORATION: COMPANY OVERVIEW 248
13.16.3 SIEMENS HEALTHINEERS 249
TABLE 240 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 249
13.16.4 PERKINELMER INC. 250
TABLE 241 PERKINELMER INC.: COMPANY OVERVIEW 250
13.16.5 SHIMADZU CORPORATION 251
TABLE 242 SHIMADZU CORPORATION: COMPANY OVERVIEW 251
13.16.6 ANTIGENIX AMERICA, INC. 251
TABLE 243 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW 251
13.16.7 ENZO LIFE SCIENCES, INC. 252
TABLE 244 ENZO LIFE SCIENCES, INC: COMPANY OVERVIEW 252
13.16.8 CAYMAN CHEMICAL LTD. 253
TABLE 245 CAYMAN CHEMICAL LTD.: COMPANY OVERVIEW 253
13.16.9 BOSTER BIOLOGICAL TECHNOLOGY 254
TABLE 246 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 254
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 255
14.1 INSIGHTS OF INDUSTRY EXPERTS 255
14.2 DISCUSSION GUIDE 256
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 261
14.4 AVAILABLE CUSTOMIZATIONS 263
14.5 RELATED REPORTS 264
14.6 AUTHOR DETAILS 266